DDInter1042 DDInter1731
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
Sunitinib {u} (Compound) resembles {v} (Compound) Metoclopramide
Sunitinib {u} (Compound) treats {v} (Disease) pancreatic cancer
Sunitinib {u} (Compound) binds {v} (Gene) SBK1
Sunitinib {u} (Compound) upregulates {v} (Gene) CRIP1
Sunitinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Sunitinib {u} (Compound) downregulates {v} (Gene) INTS3
Sunitinib {u} (Compound) causes {v} (Side Effect) Candida infection
Sunitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isoprenaline
Sunitinib (Compound) resembles Metoclopramide (Compound)
Sunitinib (Compound) treats pancreatic cancer (Disease)
Sunitinib (Compound) binds SBK1 (Gene)
Sunitinib (Compound) upregulates CRIP1 (Gene)
Sunitinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Sunitinib (Compound) downregulates INTS3 (Gene)
Sunitinib (Compound) causes Candida infection (Side Effect)
Sunitinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline